Intensity Therapeutics (NASDAQ:INTS) Issues Quarterly Earnings Results

Intensity Therapeutics (NASDAQ:INTS) released its earnings results on Tuesday. The company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.24), FiscalAI reports.

Here are the key takeaways from Intensity Therapeutics’ conference call:

• INVINCIBLE-3 is preparing to restart enrollment at limited U.S. sites within the next few months after FDA review of a revised protocol; European restart preparations are also underway.
• In the small preliminary INVINCIBLE-4 dataset, INT230-6 plus standard therapy produced a 71% pathological complete response rate versus 42% for standard therapy alone, alongside a potential reduction in severe adverse events. Management cautioned that only 14 prior patients and two patients under the amended regimen have been treated, so the signal remains early.
• Cash was $9.5 million at June 30, with an estimated operating burn of approximately $1 million per month in the second half of 2026; management said it needs roughly $30 million over several years to complete INVINCIBLE-3 and additional capital before fully reopening sites. Funding is being raised through the ATM facility, which may create shareholder dilution.
• Intensity held more than 20 meetings with potential strategic partners at the BIO International Convention and reported interest in its science and clinical programs, but emphasized that discussions are at an early stage with no partnership agreements or timelines established.

Intensity Therapeutics Stock Performance

Shares of NASDAQ:INTS traded down $0.14 during mid-day trading on Tuesday, reaching $4.15. 11,818 shares of the company traded hands, compared to its average volume of 43,504. The company’s 50 day moving average price is $4.24 and its 200-day moving average price is $5.68. The firm has a market cap of $11.21 million, a PE ratio of -0.73 and a beta of 2.76. Intensity Therapeutics has a 52 week low of $3.51 and a 52 week high of $43.50. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.86 and a quick ratio of 4.86.

Institutional Trading of Intensity Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Jane Street Group LLC purchased a new position in shares of Intensity Therapeutics during the 4th quarter valued at $26,000. Corient Private Wealth LLC bought a new stake in Intensity Therapeutics during the fourth quarter valued at about $41,000. State Street Corp raised its holdings in Intensity Therapeutics by 839.3% during the fourth quarter. State Street Corp now owns 136,200 shares of the company’s stock valued at $56,000 after acquiring an additional 121,700 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of Intensity Therapeutics by 77.8% in the fourth quarter. Geode Capital Management LLC now owns 460,248 shares of the company’s stock valued at $189,000 after acquiring an additional 201,357 shares in the last quarter. 3.74% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently weighed in on INTS shares. Weiss Ratings restated a “sell (e+)” rating on shares of Intensity Therapeutics in a report on Tuesday, July 21st. Benchmark reissued a “speculative buy” rating on shares of Intensity Therapeutics in a report on Wednesday, May 20th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $37.50.

About Intensity Therapeutics

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.